Sonoma Pharmaceuticals (SNOA) cancels meeting after no quorum
Rhea-AI Filing Summary
Sonoma Pharmaceuticals, Inc. (SNOA) reports that an adjourned special meeting of stockholders scheduled for August 19, 2026 was cancelled. As of the April 28, 2026 record date, 3,473,554 shares of common stock were entitled to vote, and a quorum required the presence in person or by proxy of 1,157,852 shares, representing one-third of the outstanding shares. A quorum was not present, so the chairman cancelled the special meeting, and the company states it will not solicit additional proxies for this meeting.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 3,473,554 shares
Quorum requirement: 1,157,852 shares
Record date: April 28, 2026
+1 more
4 metrics
Shares entitled to vote
3,473,554 shares
Common stock entitled to vote as of the April 28, 2026 record date
Quorum requirement
1,157,852 shares
One-third of issued and outstanding common shares required for quorum at the special meeting
Record date
April 28, 2026
Record date determining stockholders entitled to vote at the special meeting
Meeting date
August 19, 2026
Date the adjourned special meeting was held and then cancelled for lack of quorum
Key Terms
record date, quorum, adjourned special meeting, proxy statement
4 terms
record date financial
"On April 28, 2026, the record date for the Special Meeting, there were 3,473,554 shares"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
quorum regulatory
"A quorum was not present at the adjourned Special Meeting."
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
adjourned special meeting regulatory
"held an adjourned special meeting of stockholders (the “Special Meeting”)"
proxy statement regulatory
"pursuant to a definitive proxy statement, filed with the Securities and Exchange Commission"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
FAQ
What did Sonoma Pharmaceuticals (SNOA) announce in this Form 8-K about its special meeting?
Sonoma Pharmaceuticals announced that its August 19, 2026 adjourned special meeting of stockholders was cancelled because a quorum was not present. The company also stated it will not solicit additional proxies for this meeting.
What quorum was required for Sonoma Pharmaceuticals’ (SNOA) special meeting to proceed?
The special meeting required a quorum of 1,157,852 shares, equal to one-third of the outstanding common stock entitled to vote. Because this quorum threshold was not met, the chairman cancelled the meeting.
Did Sonoma Pharmaceuticals (SNOA) obtain a quorum at the August 19, 2026 special meeting?
No, Sonoma Pharmaceuticals did not obtain a quorum at the August 19, 2026 special meeting. Without holders of at least 1,157,852 shares present in person or by proxy, the meeting could not proceed and was cancelled.
Will Sonoma Pharmaceuticals (SNOA) continue soliciting proxies for this cancelled special meeting?
No. The company stated it will not solicit additional proxies for the adjourned special meeting. After determining that a quorum was not present, the chairman cancelled the meeting instead of further extending or re-adjourning it.
Who signed the Sonoma Pharmaceuticals (SNOA) Form 8-K for the cancelled special meeting?
The Form 8-K was signed on behalf of Sonoma Pharmaceuticals by Amy Trombly, the company’s Chief Executive Officer. Her signature indicates the filing was authorized by the registrant’s duly authorized officer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
